Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 86Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 48Myelodysplastic Syndromes 42Leukemia, Lymphocytic, Chronic, B-Cell 42Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Carcinoma, Hepatocellular 33Triple Negative Breast Neoplasms 32Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

ganitumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Insulin-Like Growth Factor I, Resistance To × Clear all
NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NantCell, Inc.

Phase 1/2 Terminated
15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

Data powered by HemOnc (CC BY 4.0) Colophon âš¡